Tempus AI (TEM) announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer’s disease research. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer’s disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Mixed options sentiment in tempus AI Inc Class A with shares up 2.05%
- Moderately bullish activity in tempus AI Inc Class A with shares up 1.99%
- Option traders moderately bearish in tempus AI Inc Class A with shares down 0.31%
- CAVA, TEM, or SMCI: Which Growth Stock Could Deliver the Highest Upside?
- Tempus AI short report addressed issues mostly known, says TD Cowen